Hookipa Pharma Inc (HOOK)
OTHER OTC:HOOK
Top Page
Hookipa Pharma
(OTC:HOOK)
Select Model
Select Model
Rating:40Underperform
Price Target:
$1.00
▲(12.36% Upside)
Action:ReiteratedDate:09/09/25
Hookipa Pharma's overall stock score is low due to severe financial difficulties, negative technical indicators, and poor valuation metrics. The company's strategic decisions to sell assets and liquidate further exacerbate the risk, making it a highly speculative investment.
Positive Factors
Strategic Partnerships
Strategic partnerships provide a recurring revenue stream through upfront and milestone payments, supporting financial stability and growth.
Negative Factors
Asset Sale and Liquidation
Asset sale and liquidation plans indicate a winding down of operations, posing a significant risk to the company's future viability and investor returns.
Read all positive and negative factors
Positive Factors
Negative Factors
Strategic Partnerships
Strategic partnerships provide a recurring revenue stream through upfront and milestone payments, supporting financial stability and growth.
Read all positive factors
Hookipa Pharma (HOOK) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$14.18M
Dividend YieldN/A
Average Volume (3M)15.71K
Price to Earnings (P/E)―
Beta (1Y)1.84
Revenue Growth-71.52%
EPS Growth1.45%
CountryUS
Employees82
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding9,930,789
10 Day Avg. Volume21,467
30 Day Avg. Volume15,706
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.49
Price to Sales (P/S)0.57
P/FCF Ratio-0.33
Enterprise Value/Market Cap-1.36
Enterprise Value/Revenue-1.30
Enterprise Value/Gross Profit-1.30
Enterprise Value/Ebitda0.36
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Hookipa Pharma Business Overview & Revenue Model
Company Description
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101,...
How the Company Makes Money
Hookipa Pharma generates revenue primarily through strategic partnerships, collaborations, and potential licensing agreements with larger pharmaceutical companies. These partnerships often involve upfront payments, milestone payments based on deve...
Hookipa Pharma Financial Statement Overview
Summary
Income Statement
15
Very Negative
Balance Sheet
35
Negative
Cash Flow
20
Very Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 14.86M | 43.95M | 20.13M | 14.25M | 18.45M | 19.58M |
| Gross Profit | 14.86M | 41.19M | 16.58M | 10.65M | 13.81M | -33.55M |
| EBITDA | -53.86M | -40.85M | -77.34M | -60.40M | -70.13M | -39.15M |
| Net Income | -56.00M | -43.50M | -81.58M | -64.92M | -75.67M | -44.08M |
Balance Sheet | ||||||
| Total Assets | 52.71M | 82.55M | 161.34M | 170.45M | 126.05M | 187.82M |
| Cash, Cash Equivalents and Short-Term Investments | 34.23M | 39.68M | 117.10M | 113.44M | 65.92M | 143.18M |
| Total Debt | 546.00K | 875.00K | 6.56M | 6.50M | 10.63M | 10.77M |
| Total Liabilities | 24.02M | 31.33M | 71.48M | 67.94M | 36.45M | 31.69M |
| Stockholders Equity | 28.68M | 51.21M | 89.86M | 102.52M | 89.59M | 156.12M |
Cash Flow | ||||||
| Free Cash Flow | -45.58M | -77.17M | -61.68M | -25.01M | -78.60M | -41.71M |
| Operating Cash Flow | -45.53M | -76.98M | -57.52M | -20.00M | -66.02M | -39.34M |
| Investing Cash Flow | -53.00K | -194.00K | -4.16M | -5.02M | -12.58M | -2.37M |
| Financing Cash Flow | -443.00K | -1.28M | 65.67M | 72.27M | -235.00K | 73.42M |
Hookipa Pharma Technical Analysis
Positive
0.89
Price Trends
1.05
Positive
0.97
Positive
0.97
Positive
Market Momentum
0.02
Negative
68.66
Neutral
99.59
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HOOK, the sentiment is Positive. The current price of 0.89 is below the 20-day moving average (MA) of 1.07, below the 50-day MA of 1.05, and below the 200-day MA of 0.97, indicating a bullish trend. The MACD of 0.02 indicates Negative momentum. The RSI at 68.66 is Neutral, neither overbought nor oversold. The STOCH value of 99.59 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HOOK.
Hookipa Pharma Risk Analysis
Hookipa Pharma disclosed 85 risk factors in its most recent earnings report. Hookipa Pharma reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Hookipa Pharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $14.64M | -0.72 | -107.58% | ― | ― | 83.95% | |
49 Neutral | $83.21M | -0.65 | -116.86% | ― | -98.25% | 63.05% | |
41 Neutral | $4.89M | -3.61 | -154.50% | ― | ― | 54.25% | |
40 Underperform | $14.18M | -2.22 | -97.61% | ― | -71.52% | 1.45% | |
39 Underperform | $389.34K | ― | -1302.82% | ― | ― | 99.09% |
* Healthcare Sector Average
HOOK
Hookipa Pharma
1.15
0.33
41.10%
KZIA
Kazia Therapeutics
7.34
3.79
106.76%
PHIO
Phio Pharmaceuticals
1.26
0.23
22.33%
WINT
Windtree Therapeutics
0.01
-1.19
-99.08%
PHGE
BiomX
3.07
-8.23
-72.83%
PLRZ
Polyrizon Ltd.
12.30
-571.95
-97.89%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.